Results 151 to 160 of about 2,291,402 (391)

RAMPTM: A Rapid, Quantitative Whole Blood Immunochromatographic Platform for Point-of-Care Testing [PDF]

, 1999
Donald E. Brooks, Dana V. Devine, Paul C Harris, Joanne E Harris, Mark E. Miller, Andrew D Olal, Linda J Spiller, Zongen C Xie   +7 more
openalex   +1 more source

Highly multiplexed digital PCR assay for simultaneous quantification of variant allele frequencies and copy number alterations of KRAS and GNAS in pancreatic cancer precursors

Molecular Oncology, EarlyView.
Combining melting curve analysis enhances the multiplexing capability of digital PCR. Here, we developed a 14‐plex assay to simultaneously measure single nucleotide mutations and amplifications of KRAS and GNAS, which are common driver genes in pancreatic cancer precursors. This assay accurately quantified variant allele frequencies in clinical samples
Junko Tanaka, Tatsuo Nakagawa, Yusuke Ono, Yoshio Kamura, Takeshi Ishida, Hidemasa Kawabata, Kenji Takahashi, Hiroki Sato, Andrew S. Liss, Yusuke Mizukami, Takahide Yokoi   +10 more
wiley   +1 more source

Point-of-Care Blood Testing [PDF]

, 1999
Barry A. Shapiro
openalex   +1 more source

A large‐scale retrospective study in metastatic breast cancer patients using circulating tumour DNA and machine learning to predict treatment outcome and progression‐free survival

Molecular Oncology, EarlyView.
There is an unmet need in metastatic breast cancer patients to monitor therapy response in real time. In this study, we show how a noninvasive and affordable strategy based on sequencing of plasma samples with longitudinal tracking of tumour fraction paired with a statistical model provides valuable information on treatment response in advance of the ...
Emma J. Beddowes, Mario Ortega Duran, Solon Karapanagiotis, Alistair Martin, Meiling Gao, Riccardo Masina, Ramona Woitek, James Tanner, Fleur Tippin, Justine Kane, Jonathan Lay, Anja Brouwer, Stephen‐John Sammut, Suet‐Feung Chin, Davina Gale, Dana W. Y. Tsui, Sarah‐Jane Dawson, Nitzan Rosenfeld, Maurizio Callari, Oscar M. Rueda, Carlos Caldas   +20 more
wiley   +1 more source

Assessment of the diagnostic performance of TrueHb® point-of-care hemometer compared with Sysmex i3 analyzer among patients at International Hospital Kampala, Uganda

Journal of Blood Medicine, 2019
Ivan Mugisha Taremwa,1 Ivan Ndeze,1 Bashir Mwambi,1 Christine Atuhairwe,2 Diana Inda Achieng,3 Bernard Natukunda41Department of Medical Laboratory Sciences, Institute of Allied Health Sciences, Clarke International University, Kampala, Uganda; 2Institute
Taremwa IM, Ndeze I, Mwambi B, Atuhairwe C, Achieng DI, Natukunda B   +5 more
doaj  

The cost-effectiveness of upfront point-of-care testing in the emergency department: a secondary analysis of a randomised, controlled trial

Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2019
Background Time-saving is constantly sought after in the Emergency Department (ED), and Point-of-Care (POC) testing has been shown to be an effective time-saving intervention.
Lara Nicole Goldstein, Mike Wells, Craig Vincent-Lambert   +2 more
doaj   +1 more source

ShcD adaptor protein drives invasion of triple negative breast cancer cells by aberrant activation of EGFR signaling

Molecular Oncology, EarlyView.
We identified adaptor protein ShcD as upregulated in triple‐negative breast cancer and found its expression to be correlated with reduced patient survival and increased invasion in cell models. Using a proteomic screen, we identified novel ShcD binding partners involved in EGFR signaling pathways.
Hayley R. Lau, Hayley S. Smith, Begüm Alural, Claire E. Martin, Laura A. New, Manali Tilak, Sara L. Banerjee, Hannah N. Robeson, Nicolas Bisson, Anne‐Claude Gingras, Jasmin Lalonde, Nina Jones   +11 more
wiley   +1 more source

Factors determining patients' intentions to use point-of-care testing medical devices for self-monitoring: the case of international normalized ratio self-testing

Patient Preference and Adherence, 2012
Syed Ghulam Sarwar Shah,1 Julie Barnett,1 Jasna Kuljis,2 Kate Hone,2 Richard Kaczmarski31Multidisciplinary Assessment of Technology Centre for Healthcare, 2Department of Information Systems and Computing, Brunel University London, Uxbridge, Middlesex, UK;
Shah SG, Barnett J, Kuljis J, Hone K, Kaczmarski R   +4 more
doaj  

Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry

Molecular Oncology, EarlyView.
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson, Emma L. Dorward, Kristyn Jurrius, Nathalie Nataren, Markus Tondl, Kay K. Myo Min, Michaelia P. Cockshell, Anahita Fouladzadeh, John Toubia, Mark DeNichilo, Delphine Merino, Claudine S. Bonder   +11 more
wiley   +1 more source

Point-of-care assessment of haemostasis after cardiopulmonary bypass [PDF]

, 1999
Michael S. Avidan, Beverley J. Hunt
openalex   +1 more source